BR112014006222A2 - esteroides vegetais e usos dos mesmos - Google Patents
esteroides vegetais e usos dos mesmosInfo
- Publication number
- BR112014006222A2 BR112014006222A2 BR112014006222A BR112014006222A BR112014006222A2 BR 112014006222 A2 BR112014006222 A2 BR 112014006222A2 BR 112014006222 A BR112014006222 A BR 112014006222A BR 112014006222 A BR112014006222 A BR 112014006222A BR 112014006222 A2 BR112014006222 A2 BR 112014006222A2
- Authority
- BR
- Brazil
- Prior art keywords
- intestinal
- drug
- conjugate
- diseases
- relates
- Prior art date
Links
- 150000003431 steroids Chemical class 0.000 title abstract 5
- 239000003814 drug Substances 0.000 abstract 7
- 229940079593 drug Drugs 0.000 abstract 7
- 208000028774 intestinal disease Diseases 0.000 abstract 4
- 230000010226 intestinal metabolism Effects 0.000 abstract 4
- 201000010099 disease Diseases 0.000 abstract 2
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 2
- 230000000968 intestinal effect Effects 0.000 abstract 2
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/54—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
- A61K47/554—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound the modifying agent being a steroid plant sterol, glycyrrhetic acid, enoxolone or bile acid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
- A61K31/57—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
- A61K31/573—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone substituted in position 21, e.g. cortisone, dexamethasone, prednisone or aldosterone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
- A61K31/575—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of three or more carbon atoms, e.g. cholane, cholestane, ergosterol, sitosterol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/06—Antihyperlipidemics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/38—Drugs for disorders of the endocrine system of the suprarenal hormones
- A61P5/44—Glucocorticosteroids; Drugs increasing or potentiating the activity of glucocorticosteroids
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07J—STEROIDS
- C07J41/00—Normal steroids containing one or more nitrogen atoms not belonging to a hetero ring
- C07J41/0033—Normal steroids containing one or more nitrogen atoms not belonging to a hetero ring not covered by C07J41/0005
- C07J41/0055—Normal steroids containing one or more nitrogen atoms not belonging to a hetero ring not covered by C07J41/0005 the 17-beta position being substituted by an uninterrupted chain of at least three carbon atoms which may or may not be branched, e.g. cholane or cholestane derivatives, optionally cyclised, e.g. 17-beta-phenyl or 17-beta-furyl derivatives
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07J—STEROIDS
- C07J71/00—Steroids in which the cyclopenta(a)hydrophenanthrene skeleton is condensed with a heterocyclic ring
- C07J71/0005—Oxygen-containing hetero ring
- C07J71/0026—Oxygen-containing hetero ring cyclic ketals
- C07J71/0031—Oxygen-containing hetero ring cyclic ketals at positions 16, 17
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07J—STEROIDS
- C07J9/00—Normal steroids containing carbon, hydrogen, halogen or oxygen substituted in position 17 beta by a chain of more than two carbon atoms, e.g. cholane, cholestane, coprostane
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07J—STEROIDS
- C07J31/00—Normal steroids containing one or more sulfur atoms not belonging to a hetero ring
- C07J31/006—Normal steroids containing one or more sulfur atoms not belonging to a hetero ring not covered by C07J31/003
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Botany (AREA)
- Diabetes (AREA)
- Endocrinology (AREA)
- Obesity (AREA)
- Pain & Pain Management (AREA)
- Rheumatology (AREA)
- Hematology (AREA)
- Steroid Compounds (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
- Medicines Containing Plant Substances (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201161535661P | 2011-09-16 | 2011-09-16 | |
| US201261675966P | 2012-07-26 | 2012-07-26 | |
| PCT/US2012/055549 WO2013040441A1 (en) | 2011-09-16 | 2012-09-14 | Plant steroids and uses thereof |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| BR112014006222A2 true BR112014006222A2 (pt) | 2017-04-11 |
Family
ID=47883793
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| BR112014006222A BR112014006222A2 (pt) | 2011-09-16 | 2012-09-14 | esteroides vegetais e usos dos mesmos |
Country Status (16)
| Country | Link |
|---|---|
| US (2) | US10086082B2 (https=) |
| EP (1) | EP2755660B1 (https=) |
| JP (2) | JP6035338B2 (https=) |
| KR (1) | KR20140093661A (https=) |
| CN (2) | CN103987390A (https=) |
| AU (1) | AU2012308332A1 (https=) |
| BR (1) | BR112014006222A2 (https=) |
| CA (1) | CA2848979C (https=) |
| EA (1) | EA201490637A1 (https=) |
| HK (1) | HK1200358A1 (https=) |
| IL (1) | IL231541A0 (https=) |
| IN (1) | IN2014CN02688A (https=) |
| MX (1) | MX2014003260A (https=) |
| PH (1) | PH12014500596A1 (https=) |
| SG (1) | SG11201400652UA (https=) |
| WO (1) | WO2013040441A1 (https=) |
Families Citing this family (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| BR112015021388A2 (pt) | 2013-03-08 | 2017-07-18 | Allergan Inc | conjugados esteroides de ciclosporina a |
| RU2015138891A (ru) | 2013-03-08 | 2017-04-11 | Аллерган, Инк. | Конъюгаты антибиотиков, напрямую связанные со стероидными препаратами |
| US10301268B2 (en) | 2014-03-13 | 2019-05-28 | The Salk Institute For Biological Studies | Analogs of fexaramine and methods of making and using |
| US10077268B2 (en) | 2014-03-13 | 2018-09-18 | Salk Institute For Biological Studies | FXR agonists and methods for making and using |
| US10238664B2 (en) | 2014-07-09 | 2019-03-26 | Duke University | Compositions and methods for the repair of myelin |
| EP4537847A3 (en) | 2017-01-13 | 2025-07-30 | Duke University | Compositions and methods for the treatment of myelin related and inflammation related diseases or disorders |
| KR102139678B1 (ko) * | 2017-11-24 | 2020-07-31 | 전북대학교 산학협력단 | N-아세틸 또는 n-아실 아미노산을 포함하는 아토피 또는 가려움증 치료용 조성물 |
| CN110051674A (zh) * | 2018-07-26 | 2019-07-26 | 中国人民解放军空军军医大学第一附属医院 | 豆甾醇在制备治疗胃癌的药物中的用途 |
Family Cites Families (13)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2000052029A1 (en) | 1999-03-04 | 2000-09-08 | Eugene Science Inc. | Water-soluble sterol derivative for inhibiting cholesterol absorption and process for preparing the same |
| EP1189924B1 (en) * | 1999-06-23 | 2004-08-18 | Forbes Medi-Tech Inc. | Conjugates of phytosterol or phytostanol with ascorbic acid and use thereof in treating or preventing cardiovascular disease |
| AU2002252387A1 (en) * | 2001-03-14 | 2002-09-24 | Lipogenics, Inc. | Novel anti-inflammatory compositions and methods of use |
| EP1385530A4 (en) | 2001-05-09 | 2005-11-09 | Mediplex Corp | FORMULATION OF AMPHIPHILENE HEPARIN DERIVATIVES FOR IMPROVING SLIME SKIN ABSORPTION |
| SE0103765D0 (sv) * | 2001-11-09 | 2001-11-09 | Astrazeneca Ab | New use |
| US20040236125A1 (en) * | 2002-09-25 | 2004-11-25 | Forbes Medi-Tech Inc. | Novel structures and compositions comprising sterols and/or stanols and specific classes of anti-inflammatory agents and use thereof in treating or preventing cardiovascular disease, its underlying conditions including hyperlipidemia and other disorders having inflammation as part of their aetiology or presentation |
| WO2004095926A2 (en) | 2003-04-28 | 2004-11-11 | Monsanto Technology, Llc | Treatment of plants and plant propagation materials with an antioxidant to improve plant health and/or yield |
| US20050234025A1 (en) * | 2004-04-20 | 2005-10-20 | Forbes Medi-Tech Inc. | Compositions comprising one or more policosanols and/or policosanoic acids combined with sterol and/or steroid based ascorbic acid derivatives, and uses thereof |
| WO2006099445A2 (en) * | 2005-03-14 | 2006-09-21 | Massachusetts Institute Of Technology | Nanocells for diagnosis and treatment of diseases and disorders |
| AU2007299705B2 (en) * | 2006-09-22 | 2012-09-06 | Dharmacon, Inc. | Duplex oligonucleotide complexes and methods for gene silencing by RNA interference |
| JP2010509355A (ja) * | 2006-11-06 | 2010-03-25 | ジャイナ ファーマシューティカルズ，インコーポレーテッド | グッグルリン脂質の方法および組成物 |
| US8188060B2 (en) * | 2008-02-11 | 2012-05-29 | Dharmacon, Inc. | Duplex oligonucleotides with enhanced functionality in gene regulation |
| WO2011109472A1 (en) | 2010-03-02 | 2011-09-09 | Imagenetix, Inc. | Compositions comprising myristic acid and uses thereof |
-
2012
- 2012-09-14 US US14/345,028 patent/US10086082B2/en not_active Expired - Fee Related
- 2012-09-14 BR BR112014006222A patent/BR112014006222A2/pt active Search and Examination
- 2012-09-14 MX MX2014003260A patent/MX2014003260A/es not_active Application Discontinuation
- 2012-09-14 WO PCT/US2012/055549 patent/WO2013040441A1/en not_active Ceased
- 2012-09-14 PH PH1/2014/500596A patent/PH12014500596A1/en unknown
- 2012-09-14 CN CN201280056467.7A patent/CN103987390A/zh active Pending
- 2012-09-14 EA EA201490637A patent/EA201490637A1/ru unknown
- 2012-09-14 JP JP2014530888A patent/JP6035338B2/ja not_active Expired - Fee Related
- 2012-09-14 KR KR1020147009670A patent/KR20140093661A/ko not_active Withdrawn
- 2012-09-14 AU AU2012308332A patent/AU2012308332A1/en not_active Abandoned
- 2012-09-14 CN CN201811306193.8A patent/CN109384825A/zh active Pending
- 2012-09-14 CA CA2848979A patent/CA2848979C/en not_active Expired - Fee Related
- 2012-09-14 HK HK15101045.6A patent/HK1200358A1/xx unknown
- 2012-09-14 SG SG11201400652UA patent/SG11201400652UA/en unknown
- 2012-09-14 IN IN2688CHN2014 patent/IN2014CN02688A/en unknown
- 2012-09-14 EP EP12832645.1A patent/EP2755660B1/en active Active
-
2014
- 2014-03-16 IL IL231541A patent/IL231541A0/en unknown
-
2016
- 2016-10-31 JP JP2016212948A patent/JP2017019871A/ja active Pending
-
2018
- 2018-08-29 US US16/116,713 patent/US20190083632A1/en not_active Abandoned
Also Published As
| Publication number | Publication date |
|---|---|
| US20150141390A1 (en) | 2015-05-21 |
| IN2014CN02688A (https=) | 2015-07-03 |
| SG11201400652UA (en) | 2014-09-26 |
| CN103987390A (zh) | 2014-08-13 |
| JP2014526515A (ja) | 2014-10-06 |
| JP6035338B2 (ja) | 2016-11-30 |
| CA2848979A1 (en) | 2013-03-21 |
| PH12014500596A1 (en) | 2014-04-21 |
| EA201490637A1 (ru) | 2014-11-28 |
| CA2848979C (en) | 2019-11-05 |
| EP2755660A1 (en) | 2014-07-23 |
| US10086082B2 (en) | 2018-10-02 |
| IL231541A0 (en) | 2014-04-30 |
| AU2012308332A1 (en) | 2014-04-10 |
| MX2014003260A (es) | 2014-09-08 |
| EP2755660A4 (en) | 2015-03-18 |
| KR20140093661A (ko) | 2014-07-28 |
| CN109384825A (zh) | 2019-02-26 |
| JP2017019871A (ja) | 2017-01-26 |
| EP2755660B1 (en) | 2019-11-06 |
| HK1200358A1 (en) | 2015-08-07 |
| US20190083632A1 (en) | 2019-03-21 |
| WO2013040441A1 (en) | 2013-03-21 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| BR112014006222A2 (pt) | esteroides vegetais e usos dos mesmos | |
| Zhang et al. | Evaluating the effects of mitochondrial autophagy flux on ginsenoside Rg2 for delaying D-galactose induced brain aging in mice | |
| Liang et al. | Protective roles and mechanisms of Dendrobium officinal polysaccharides on secondary liver injury in acute colitis | |
| Gao et al. | Shuang-Huang-Lian exerts anti-inflammatory and anti-oxidative activities in lipopolysaccharide-stimulated murine alveolar macrophages | |
| BR112013027119A8 (pt) | novos conjugados ligante-droga (adcs) e uso dos mesmos | |
| BR112014027571A2 (pt) | métodos para o tratamento de retinopatia diabética e outras doenças oftalmológicas | |
| BR112015007778A2 (pt) | profármacos neutralizantes de vegf para o tratamento de condições oculares | |
| MX2015002239A (es) | Formulacion oftalmica de lipido polioxilo o de acido graso polioxilo y tratamiento de padecimientos oculares. | |
| Wang et al. | Ginsenoside Rg1 reduces aldosterone-induced autophagy via the AMPK/mTOR pathway in NRK-52E cells | |
| HK1209633A1 (en) | Compositions and methods for treating diabetes | |
| BR112012005044A2 (pt) | composições que compreendem tramadol e celecoxib no tratamento de dor. | |
| BR112015003729A8 (pt) | Composto de fórmula estrutural i; composição farmacêutica; método de tratamento de uma doença mediada por caminho do hif; método de tratamento de uma doença causada por proliferação anormal de células; e método para alcançar um efeito em um paciente | |
| BR112013006355A2 (pt) | profármacos de éster de [3-(1-(1h-imidazol-4-il)etil-2-metilfenil] metanol para tratar doenças retinais | |
| BR112013023970A2 (pt) | composição farmacêutica, dispositivo, inibidor de hdac, kit, método de pré-tratamento de um ser humano que sofre de câncer e método de avaliação do efeito de uma substância sobre a sensibilidade a chop de linhagens celulares | |
| Meng et al. | Ursolic acid protects hepatocytes against lipotoxicity through activating autophagy via an AMPK pathway | |
| BR112023020626A2 (pt) | Agentes de rnai para inibir a expressão do receptor para produtos finais de glicação avançada, composições dos mesmos e métodos de uso | |
| Ma et al. | Therapeutic effect of gypenosides on antioxidant stress injury in orbital fibroblasts of graves’ orbitopathy | |
| CO7101244A2 (es) | Fenilimidazopirazoles sustituidos y su uso | |
| Feng et al. | Glycyrrhetinic acid reverses antibiotic-induced intestinal epithelial injury through RNA-binding protein human antigen R (HuR) | |
| Song et al. | The active components of traditional Chinese medicines regulate the multi-target signaling pathways of metabolic dysfunction-associated fatty liver disease | |
| Zhang et al. | Stevioside Improves Liver Insulin Resistance in Prediabetic Mice via IRS1/PI3K/AKT Signaling Pathway | |
| BR112015001627A2 (pt) | composição farmacêutica, respectivos usos e método para diminuir a frequência de micção | |
| Hubková et al. | Hydroxybenzoic acids and their derivatives as peroxynitrite scavengers | |
| Zhang et al. | Ophiopogonin D improves oxidative stress and mitochondrial dysfunction in pancreatic β cells induced by hydrogen peroxide through Keap1/Nrf2/ARE pathway in diabetes mellitus | |
| BR112012028652A2 (pt) | hidroxialquilbenzilpirazois e seu uso |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| B07D | Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette] | ||
| B06F | Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette] | ||
| B08F | Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette] | ||
| B08K | Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette] |
Free format text: EM VIRTUDE DO ARQUIVAMENTO PUBLICADO NA RPI 2479 DE 10-07-2018 E CONSIDERANDO AUSENCIA DE MANIFESTACAO DENTRO DOS PRAZOS LEGAIS, INFORMO QUE CABE SER MANTIDO O ARQUIVAMENTO DO PEDIDO DE PATENTE, CONFORME O DISPOSTO NO ARTIGO 12, DA RESOLUCAO 113/2013. |
|
| B07E | Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette] |
Free format text: NOTIFICACAO DE ANUENCIA RELACIONADA COM O ART 229 DA LPI |